Bill and Melinda Gates pledge biggest-ever charitable donation - $10 billion - in call for 'Decade of Vaccines'

29 January 2010

Surpassing even their own previous enormous give aways, Bill (Microsoft founder and philanthropist and Melinda Gates today announced that their foundation will commit $10 billion over the next 10 years to help research, develop and deliver vaccines for the world's poorest countries, making this the largest ever single charitable donation.

The Gateses said that increased investment in vaccines by governments and the private sector could help developing countries dramatically reduce child mortality by the end of the decade, and they called for others to help fill critical financing gaps in both research funding and childhood immunization programs. The new funding is in addition to the $4.5 billion that the Gates Foundation has already committed to vaccine research, development and delivery over the last 10 years.

Applauded by WHO, but needs to be matched by govts/private sector

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical